NCT02977507

Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma

Randomized, Double-blinded, Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Subjects With Moderate Facial Melasma

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to evaluate the efficacy and tolerability of Lytera 2.0 versus 4% hydroquinone in the improvement of the appearance of moderate facial melasma.

Conditions

• Melasma

Interventions

Type	Name	Description
OTHER	Lytera 2.0	Lytera 2.0 applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
DRUG	4% Hydroquinone Topical Cream	4% Hydroquinone Topical Cream applied to the affected areas twice a day, in the morning and evening, every day for 12 weeks.
OTHER	SkinMedica Facial Cleanser	SkinMedica facial cleanser applied to the face as directed.
OTHER	SkinMedica Rejuvenative Moisturizer	SkinMedica rejuvenative moisturizer applied to the face as directed.
OTHER	SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 Sunscreen	SkinMedica Essential Defense Mineral Shield Broad Spectrum SPF 35 sunscreen applied to the face as directed.

Timeline

• Start date: 2016-12-13
• Primary completion: 2017-10-09
• Completion: 2017-10-09
• First posted: 2016-11-30
• Last updated: 2018-12-19
• Results posted: 2018-11-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study